<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="55923"><DrugName>S-364735</DrugName><DrugSynonyms><Name><Value>364735</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HIV integrase inhibitors (2), Shionogi/GlaxoSmithKline</Value></Name><Name><Value>GSK-364735</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>364735-C</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>S-364735</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19898">Shionogi &amp; Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="28355">GlaxoSmithKline plc</Company><Company id="30251">Shionogi-GlaxoSmithKline Pharmaceuticals LLC</Company></CompaniesSecondary><CrossReferences><SourceEntity id="55923" type="Drug"><TargetEntity id="424303" type="siDrug">GSK-364735</TargetEntity></SourceEntity><SourceEntity id="19898" type="Company"><TargetEntity id="4295876951" type="organizationId">Shionogi &amp; Co Ltd</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="30251" type="Company"><TargetEntity id="5036229120" type="organizationId">Shionogi-GlaxoSmithKline Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"></TargetEntity><TargetEntity id="042" type="ICD9"></TargetEntity><TargetEntity id="10020161" type="MEDDRA"></TargetEntity><TargetEntity id="D015658" type="MeSH"></TargetEntity><TargetEntity id="-841965209" type="omicsDisease"></TargetEntity><TargetEntity id="862" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1671" type="Action"><TargetEntity id="435" type="Mechanism">HIV Integrase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00935" type="ciTarget"><TargetEntity id="5563997851553483" type="siTarget">Reverse Transcriptase Human immunodeficiency virus type 1</TargetEntity><TargetEntity id="17809854121553483" type="siTarget">Integrase Gag-Pol polyprotein</TargetEntity><TargetEntity id="-312403773" type="omicsTarget"></TargetEntity><TargetEntity id="-213884076" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="158">HIV infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="1671">HIV integrase inhibitor</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2017-08-21T10:09:36.000Z</LastModificationDate><ChangeDateLast>2013-04-03T00:00:00.000Z</ChangeDateLast><AddedDate>2006-08-15T11:21:09.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19898" linkType="Company"&gt;Shionogi&lt;/ulink&gt; and &lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt; (GSK), through their joint venture &lt;ulink linkID="30251" linkType="Company"&gt;Shionogi-GlaxoSmithKline Pharmaceuticals&lt;/ulink&gt;, were developing S-364735 (364735, GSK-364735), an oral HIV integrase inhibitor, for the potential treatment of HIV infection. By August 2006, doses had been selected for a phase II trial in HIV-infected adults, which was scheduled to begin in late 2006  [&lt;ulink linkID="683892" linkType="Reference"&gt;683892&lt;/ulink&gt;]; by October 2006, the trial was underway [&lt;ulink linkID="755838" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="756478" linkType="Reference"&gt;756478&lt;/ulink&gt;]. However, by July 2007, development of S-364735 (structure shown) had been discontinued based on the results of a long-term preclinical safety study. Shionogi reported that Shionogi-GSK would continue to collaborate on research to identify superior back up compounds and in conducting clinical trials [&lt;ulink linkID="820740" linkType="Reference"&gt;820740&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Shionogi-GlaxoSmithKline Pharmaceuticals  had also been investigating two other integrase inhibitors for the potential treatment of HIV infection, &lt;ulink linkID="46024" linkType="Drug"&gt;1838&lt;/ulink&gt; and &lt;ulink linkID="29171" linkType="Drug"&gt;S-1360&lt;/ulink&gt;. However, development of S-1360 was discontinued in July 2003 [&lt;ulink linkID="498711" linkType="Reference"&gt;498711&lt;/ulink&gt;], and by August 2004, development of 1838 had also been discontinued [&lt;ulink linkID="619001" linkType="Reference"&gt;619001&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In October 2006, a placebo-controlled, randomized, double-blind, dose-ranging phase II trial (NCT00398125, GRZ107460) was initiated in subjects (expected n = 60) with HIV-1 in the US. The subjects were to receive S-364735 over 10 days. The primary endpoint was a change in viral load from day 1 to day 11 and the amount of drug in blood on days 1 and 10 and secondary endpoints included immunologic effect, development of resistance mutations and drug levels in semen for a group of patients. The study was still recruiting in January 2007 [&lt;ulink linkID="756478" linkType="Reference"&gt;756478&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2006, the agent was in phase I trials in the US  [&lt;ulink linkID="684138" linkType="Reference"&gt;684138&lt;/ulink&gt;]. By August 2006, a phase I study to evaluate safety and pharmacokinetics had been conducted in healthy volunteers in  the US, and doses for a phase II study had been selected. At that time, results were due to be presented at a conference in 2007 [&lt;ulink linkID="683892" linkType="Reference"&gt;683892&lt;/ulink&gt;]. In March 2007, clinical data were reported. The plasma concentration of S-364735 exceeded the targeted treatment trough value by administration of over 50 mg BID, no drug inhibition was seen, there was no induction against metabolic enzymes and a food effect was observed for plasma concentration. The studies confirmed safety and good tolerability and no severe adverse side effects were observed [&lt;ulink linkID="823685" linkType="Reference"&gt;823685&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2015, preclinical data were presented at the 249th ACS meeting in Denver, CO. The best dose of GSK-364735 was 200 mg which showed antiviral activity but was not differentiated in monkey livers [&lt;ulink linkID="1642425" linkType="Reference"&gt;1642425&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, data from in vitro studies were reported. S-364735 exhibited strong anti-HIV activity in inhibiting virus replication at 1 nM. It was also found that the resistant mutation was slow to emerge [&lt;ulink linkID="823685" linkType="Reference"&gt;823685&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2001, Shionogi and GSK entered into an agreement to codevelop compounds under a joint venture company, Shionogi-GlaxoSmithKline Pharmaceuticals [&lt;ulink linkID="498711" linkType="Reference"&gt;498711&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Patent &lt;ulink linkID="PA3012763" linkType="Patent"&gt;WO-2005077050 &lt;/ulink&gt;entitled 'New 2-oxo-1,5-naphthyridine-3-carboxamide derivatives are HIV integrase inhibitors - useful for the treatment and prevention of HIV infection, AIDS and ARC' covers HIV integrase inhibitors, for the treatment and prevention of AIDS and/or ARC.&lt;/para&gt;&lt;para&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="30251">Shionogi-GlaxoSmithKline Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-07-30T00:00:00.000Z</StatusDate><Source id="820740" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-07-30T00:00:00.000Z</StatusDate><Source id="820740" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-07-31T00:00:00.000Z</StatusDate><Source id="684138" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30251">Shionogi-GlaxoSmithKline Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-07-31T00:00:00.000Z</StatusDate><Source id="684138" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-10-31T00:00:00.000Z</StatusDate><Source id="756478" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30251">Shionogi-GlaxoSmithKline Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-10-31T00:00:00.000Z</StatusDate><Source id="756478" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00935"><Name>HIV integrase</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1642425" linkType="reference" linkID="1642425"&gt;1642425&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="19898">Shionogi &amp; Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cn1c2cc(cnc2c(c(c1=O)C(=O)NCCO)O)Cc3ccc(cc3)F</Smiles></StructureSmiles><Deals><Deal id="111437" title="Shionogi-GlaxoSmithKline Pharmaceuticals to develop and market Shionogi compounds "></Deal></Deals><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>